Özet Amaç: Meningiomlar biyolojik potansiyeli ve klinik davranışı ile geniş bir tümör grubunu temsil etmektedir. Santral sinir sisteminin en sık görülen tümörleri olup, atipik ve malign meningiom tiplerinin nüks oranı yüksektir. Son yıllarda nüksü önceden tahmin etmek amacıyla Ki-67 ve PCNA gibi proliferasyon belirleyicilerinin meningiomlarda yaygın olarak kullanıldığı görülmektedir. Gereç ve yöntem: Bu çalışmada patoloji bölümünde tanı almış 55 meningiom olgusu WHO 2000e göre yeniden sınıflandırıp histolojik alt tipleri ve gradeleri belirlendi. Seçilmiş parafin bloklardan hazırlanan kesitlere immünhistokimyasal olarak PCNA, Ki-67, EMA, vimentin ve progesteron reseptörü uygulanıp meningiomlardaki değeri araştırıldı. Bulgular: PCNA ve Ki-67 değerleri benign meningiomlarda, atipik ve malign meningiomlara göre düşük olması istatiksel olarak anlamlı bulundu (p
Abstract Purpose: Meningiomas with their potential biological and clinical behavior represents a broad brand group of tumors. Meningiomas are the most seen benign tumors of the central nervous system and types of atypical and malignant meningioma recurrence rate is high. In recent years, proliferation markers such as Ki-67 and PCNA are commonly used in meningiomas in order to predict recurrence.
Materials and methods: In this study, 55 meningioma cases diagnosed in pathology departmant were reclassified according to the WHO 2000 and their histological subtypes and grades were determined. sections from selected paraffin blocks were immunostained with PCNA, Ki-67, EMA, vimentine, and progesterone receptor (PR); and their values in meningioms were investigated. Results: PCNA and Ki-67 values of benign meningiomas are lower than the atypical and malignant meningioms as statistically significant (p<0.05). In addition, the high values of progesterone receptor positivity on benign meningiomas and the lower levels of it on malignant and atypical meningiomas are considered to be statistically significant as well (p<0.05). Conclusion: PCNA and Ki-67 proliferation rates of atypical and malignant meningiomas are observed to be higher than the benign meningioms. Benign meningiomas with high values of Ki-67 and PCNA should be observed with regard to recurrence although they are completely resected. Progesterone receptor positivity was associated with the differentiation of the tumor and prognosis alone is not enough, however in the differential diagnosis of the tumor was thought to be a good alternative to EMA and vimentine.
1. Rosenbium MK, BilbOA JM, Ang LC. Neuromuscular system. In: Rosai J,Ed. Ackermans surgical pathology. 9rd ed. St. Louis: Mosby, 2004;2564-2572.
2. Russel DS, Rubinstein LJ. Pathology of tumours of the nervous system. İn: Baltimore, 5rd ed. Lippincott Williams&Wilkins:London, 1989;452-453.
3. Kepes JJ. Meningioma: biology, pathology and differential diagnosis. In Masson: New York, 1982; 116-119.
4. Adegbite AB, Khan MI, Paine KW, Tan LK. The recurrence of intracranial meningiomas after surgical treatment. J Neurosurg 1983;58:51-56.
5. Rohringer M, Sutherland GR, Louw DF, Sima AA. Incidence and clinicopathological features of meningioma. J Neurosurg 1989;71:665-672.
6. Chen WY, Liu HC. Atypical (anaplastic) meningioma. Relationship between histologic features and recuurence: clinicopathologic study. Clin Neuropathol 1990;9:74-81.
7. Maes L, Kalala JP, Cornelissen M, De Ridder L. PCNA, Ki-67 and hTERT in residual benign meningiomas. In Vivo 2006;20:271-275.
8. Takeuchi H, Kubota T, Kabuto M, Kitai R, Nozaki J, Yamashita J. Prediction of recurence in histologically benign meningiomas: proliferating cell nuclear antigen and Ki-67 immünohistochemical study. Surg Neurol 1997;48:501-506.
9. Bravo R. Synthesis of the nuclear protein cyclin (PCNA) and its relationship with DNA replication. Exp Cell Res 1986;163:287-293.
10. Gerdes J, Lemke H, Baisch H, Wacker H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation- associated human nuclear antigen defined by the monoclonal antibody Ki-67. Immunol 1984;133:1710- 1715.
11. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20.
12. Kayaselçuk F, Zorludemir S, Gümürdühü D, Zeren H, Erman T. PCNA and Ki-67 in central nervous system tumors: correlation with the histological type and grade. J Neurooncol 2002;57:115-121.
13. Suri VS, Tatke M, Singh D, Sharma A. Histological spectrum of epandymomas and correlation of p53 and Ki-67 expression with epandymoma grade and subtype. Indian J Cancer 2004:2:66-71.
14. Hsu DW, Prado FS, Efird JT, Linggood RM, Hedley- Whyte ET. Prognostic significance of proliferative indices in meningiomas. J Neuropathol Exp Neurol 1994;53:247-255.
15. Siegers HP, Zuber P, Hamou MF, van Melle GD, de Tribolet N. The implications of the heterogeneous distribution of Ki-67 labelled cells in meningiomas. Br J Neurosurg 1989;3:101-107.
16. Sasaki A, Naganuma H, Kimura R, et al. Proliferating cell nuclear antigen (PCNA) immunostaining as an alternative to bromodeoxyuridine (BrdU) immunostaining for brain tumours in paraffin embedded sections. Acta Neurochir 1992;117:178-181.
17. Cobb MA, Husain M, Andersen BJ, Al-Mefty O. Significance of proliferating cell nuclear antigen in predicting recurrence of intracranial meningioma. J Neurosurg 1996;84:85-90.
18. de la Monte SM, Flickinger J, Linggood RM: Histopathologic features predicting recurrence of meningiomas following subtotal resection. Am J Surg Pathol 1986;10:836- 843.
19. Jaaskelainen J, Haltia M, Servo A: Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol 1986;25:233- 242.
20. Som PM, Sacher M, strenger SW, Biller HF, Malis LI: Benign metastasizing meningiomas. AJNR 1987;8:127-130.
21. Christensen D, Laursen H, Klinken L. Prediction of recurrence in meningiomas after surgical treatment: a quantitative approach. Acta Neuropathol 1983;61: 130-134.